1 Hentrich H, Kaiser R, Gottsberger G. Floral biology and reproductive isolation by floral scent in three sympatric aroid species in French Guiana. Plant Biol, 2010, 12: 587-596
[2]
2 Singh A D, Turell M E, Topham A K. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology, 2011, 118: 1881-1885
[3]
3 Triozzi P L, Eng C, Singh A D. Targeted therapy for uveal melanoma. Cancer Treat Rev, 2008, 34: 247-258
[4]
4 Bedikian A Y. Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin, 2006, 46: 151-166
[5]
5 Kujala E, M？kitie T, Kivel？ T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci, 2003, 44: 4651-4659
[6]
6 Shields C L, Shields J A. Ocular melanoma: relatively rare but requiring respect. Clin Dermatol, 2009, 27: 122-133
[7]
7 Alizadeh H, Howard K, Mellon J, et al. Reduction of liver metastasis of intraocular melanoma by interferon-beta gene transfer. Invest Ophthalmol Vis Sci, 2003, 44: 3042-3051
[8]
8 Andrawiss M, Maron A, Beltran W, et al. Adenovirus-mediated gene transfer in canine eyes: a preclinical study for gene therapy of human uveal melanoma. J Gene Med, 2001, 3: 228-239
[9]
9 Huang X, Jia R, Zhao X, et al. Recombinant oncolytic adenovirus H101 combined with siBCL2: cytotoxic effect on uveal melanoma cell lines. Brit J Ophthalmol, 2012, 96: 1331-1338
[10]
10 Zhou Y, Song X, Jia R, et al. Radiation-inducible human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy: a novel treatment for radioresistant uveal melanoma. Pigment Cell Melanoma Res, 2010, 23: 661-674
[11]
11 Song X, Zhou Y, Jia R, et al. Inhibition of retinoblastoma in vitro and in vivo with conditionally replicating oncolytic adenovirus H101. Invest Ophthalmol Vis Sci, 2010, 51: 2626-2635
[12]
12 Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets, 2007, 7: 141-148
[13]
13 Cun B, Song X, Jia R, et al. Combination of oncolytic adenovirus and dacarbazine attenuates antitumor ability against uveal melanoma cells via cell cycle block. Cancer Biol Ther, 2012, 13: 77-84
[14]
14 Song X, Wang H, Jia R, et al. Combined treatment with an oncolytic adenovirus and antitumor activity of vincristine against retinoblastoma cells. Int J Mol Sci, 2012, 13: 10736-10749
[15]
15 Jia R, Jiao Z, Xu X, et al. Functional significance of B7-H1 expressed by human uveal melanoma cells. Mol Med Rep, 2011, 4: 163-167
[16]
16 Zhang H, Wang H, Zhang J, et al. Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors. Mol Ther, 2009, 17: 57-64
[17]
17 Huang X, Wang L, Zhang H, et al. Therapeutic efficacy by targeting correction of Notch1-induced aberrants in uveal tumors. PLoS One, 2012, 7: e44301
[18]
18 Thomas M A, Spencer J F, Toth K, et al. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol Ther, 2008, 16: 1665-1673
[19]
19 DePace N. Sulla scomparsa di un enorme cancro vegetante del collo dell''utero senza cura chirurgia. Article in Italian. Ginecologia, 1912, 9: 82-89
[20]
20 Martuza R L, Malick A, Markert J M, et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science, 1991, 252: 854-856
[21]
21 Eager R M, Nemunaitis J. Clinical development directions in oncolytic viral therapy. Cancer Gene Ther, 2011, 18: 305-317
[22]
22 Hammill A M, Conner J, Cripe T P. Oncolytic virotherapy reaches adolescence. Pediatr Blood Cancer, 2010, 55: 1253-1263
[23]
23 Breitbach C J, Reid T, Burke J, et al. Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. Cytokine Growth Factor Rev, 2010, 21: 85-89
[24]
24 Vasey P A, Shulman L N, Campos S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol, 2002, 20: 1562-1569
[25]
25 Chiocca E A, Abbed K M, Tatter S, et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther, 2004, 10: 958-966
[26]
26 Patel M R, Kratzke R A. Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Transl Res, 2013, 161: 355-364
[27]
27 Cherubini G, Petouchoff T, Grossi M, et al. E1B55K-deleted adenovirus (ONYX-015) overrides G1/S and G2/M checkpoints and causes mitotic catastrophe and endoreduplication in p53-proficient normal cells. Cell Cycle, 2006, 5: 2244-2252
